<br>        INCLUSION CRITERIA:<br><br>          -  Signed informed consent;<br><br>          -  Patients must be 18 years old;<br><br>          -  Subjects must have stage IIIB or IV NSCLC .<br><br>          -  Recurrent or persistent NSCLC following one previous line of cytotoxic chemotherapy.<br><br>          -  Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-2;<br><br>          -  Life expectancy of 12 weeks;<br><br>          -  Have adequate organ function baseline laboratory values for inclusion;<br><br>        EXCLUSION CRITERIA:<br><br>          -  History of other malignancy. Subjects who have been disease-free for 5 years, or<br>             subjects with a history of completely resected non-melanoma skin cancer or<br>             successfully treated in situ carcinoma are eligible;<br><br>          -  Known history of or clinical evidence of central nervous system (CNS) metastases or<br>             leptomeningeal carcinomatosis except for individuals who have previously treated CNS<br>             metastases, are asymptomatic, and have had no requirement for steroids or antiseizure<br>             medication for = 3 months prior to study enrollment.<br><br>          -  Peripheral neuropathy of grade 3 or higher;<br><br>          -  Concurrent cancer therapy (chemotherapy, radiation therapy, surgery, immunotherapy,<br>             biologic therapy, hormonal therapy, and tumor embolization).<br><br>          -  Prior exposure to pemetrexed or an EGFR inhibitor in combination with 5-FU or a 5FU<br>             prodrug.<br>      ;<br>        INCLUSION CRITERIA:<br><br>          -  Signed informed consent;<br><br>          -  Patients must be 18 years old;<br><br>          -  Subjects must have stage IIIB or IV NSCLC .<br><br>          -  Recurrent or persistent NSCLC following one previous line of cytotoxic chemotherapy.<br><br>          -  Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-2;<br><br>          -  Life expectancy of 12 weeks;<br><br>          -  Have adequate organ function baseline laboratory values for inclusion;<br><br>        EXCLUSION CRITERIA:<br><br>          -  History of other malignancy. Subjects who have been disease-free for 5 years, or<br>             subjects with a history of completely resected non-melanoma skin cancer or<br>             successfully treated in situ carcinoma are eligible;<br><br>          -  Known history of or clinical evidence of central nervous system (CNS) metastases or<br>             leptomeningeal carcinomatosis except for individuals who have previously treated CNS<br>             metastases, are asymptomatic, and have had no requirement for steroids or antiseizure<br>             medication for = 3 months prior to study enrollment.<br><br>          -  Peripheral neuropathy of grade 3 or higher;<br><br>          -  Concurrent cancer therapy (chemotherapy, radiation therapy, surgery, immunotherapy,<br>             biologic therapy, hormonal therapy, and tumor embolization).<br><br>          -  Prior exposure to pemetrexed or an EGFR inhibitor in combination with 5-FU or a 5FU<br>             prodrug.<br>      ;<br>        INCLUSION CRITERIA:<br><br>          -  Signed informed consent;<br><br>          -  Patients must be 18 years old;<br><br>          -  Subjects must have stage IIIB or IV NSCLC .<br><br>          -  Recurrent or persistent NSCLC following one previous line of cytotoxic chemotherapy.<br><br>          -  Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-2;<br><br>          -  Life expectancy of 12 weeks;<br><br>          -  Have adequate organ function baseline laboratory values for inclusion;<br><br>        EXCLUSION CRITERIA:<br><br>          -  History of other malignancy. Subjects who have been disease-free for 5 years, or<br>             subjects with a history of completely resected non-melanoma skin cancer or<br>             successfully treated in situ carcinoma are eligible;<br><br>          -  Known history of or clinical evidence of central nervous system (CNS) metastases or<br>             leptomeningeal carcinomatosis except for individuals who have previously treated CNS<br>             metastases, are asymptomatic, and have had no requirement for steroids or antiseizure<br>             medication for = 3 months prior to study enrollment.<br><br>          -  Peripheral neuropathy of grade 3 or higher;<br><br>          -  Concurrent cancer therapy (chemotherapy, radiation therapy, surgery, immunotherapy,<br>             biologic therapy, hormonal therapy, and tumor embolization).<br><br>          -  Prior exposure to pemetrexed or an EGFR inhibitor in combination with 5-FU or a 5FU<br>             prodrug.<br>      ;<br>        INCLUSION CRITERIA:<br><br>          -  Signed informed consent;<br><br>          -  Patients must be 18 years old;<br><br>          -  Subjects must have stage IIIB or IV NSCLC .<br><br>          -  Recurrent or persistent NSCLC following one previous line of cytotoxic chemotherapy.<br><br>          -  Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-2;<br><br>          -  Life expectancy of 12 weeks;<br><br>          -  Have adequate organ function baseline laboratory values for inclusion;<br><br>        EXCLUSION CRITERIA:<br><br>          -  History of other malignancy. Subjects who have been disease-free for 5 years, or<br>             subjects with a history of completely resected non-melanoma skin cancer or<br>             successfully treated in situ carcinoma are eligible;<br><br>          -  Known history of or clinical evidence of central nervous system (CNS) metastases or<br>             leptomeningeal carcinomatosis except for individuals who have previously treated CNS<br>             metastases, are asymptomatic, and have had no requirement for steroids or antiseizure<br>             medication for = 3 months prior to study enrollment.<br><br>          -  Peripheral neuropathy of grade 3 or higher;<br><br>          -  Concurrent cancer therapy (chemotherapy, radiation therapy, surgery, immunotherapy,<br>             biologic therapy, hormonal therapy, and tumor embolization).<br><br>          -  Prior exposure to pemetrexed or an EGFR inhibitor in combination with 5-FU or a 5FU<br>             prodrug.<br>